Targeting ALDH1 in breast CSCs with ATRA or N,N-diethylaminobenzaldehyde (DEAB) combined with doxorubicin or paclitaxel therapy and radiation therapy significantly reduced tumor cell viability (38). This evidence concerns the gene ALDH1A1 and neoplasm.